Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies
Journal of the American Society of Nephrology · 2025-04 · 36 (4) · 668-678
DOI: 10.1681/asn.0000000520 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 16.10.2024. Verfasst von Philipp Gauckler und 49 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Key Points Fifty-five percent of patients achieve long-term remission after rituximab treatment. This is influenced by maintenance therapy with rituximab. A substantial reduction of annualized relapse rate and concomitant immunosuppression was observed after rituximab treatment.
Background
Long-term outcomes of rituximab-treated adult patients with podocytopathies (either minimal change disease or FSGS) are largely unknown.
Methods
A retrospective study at 30 nephrology departments from 15 countries worldwide included rituximab-treated adults with primary podocytopathies and a minimum clinical follow-up of 36 months. The primary outcome was relapse-free survival at 36 months.
Results
One hundred eighty-three adult patients ( n =64 with FSGS and n =119 with minimal change disease) with difficult-to-treat nephrotic syndrome (68% steroid-dependent/frequently relapsing, 22% steroid-resistant, 85% previously treated with two or more lines of immunosuppressive therapy) were treated with rituximab as part of a remission induction regimen. Complete or partial remission at 6 months after rituximab treatment was achieved in 82%. Eighty-three of 151 (55%) initial responders achieved long-term relapse-free survival over 3 years. Maintenance therapy with rituximab was associated with a better relapse-free survival (hazard ratio, 2.05; 95% confidence interval [CI], 1.07 to 3.91), irrespective of the dosing regimen. At 36 months, 61% of initial responders receiving maintenance therapy with rituximab achieved long-term relapse-free survival and withdrawal of all concomitant immunosuppressive medication compared with 36% of patients without maintenance treatment (odds ratio, 2.69; 95% CI, 1.27 to 5.73). Relapses per year were reduced from an annual relapse rate of 1.0 (95% CI, 1.0 to 1.7) before to 0.17 (95% CI, 0.00 to 0.24) relapses per year after rituximab initiation. Over the 36 months of follow-up, a stable course of eGFR was observed in those who initially responded with either complete or partial remission, whereas nonresponders experienced a reduction in eGFR reaching −11 (95% CI, −18 to −8) ml/min per 1.73 m 2 .
Conclusions
Rituximab facilitated achievement of initial and long-term response in a majority of adult patients with difficult-to-treat podocytopathies. Maintenance treatment with rituximab was further associated with long-term relapse-free survival over 3 years. Nonresponse to initial rituximab treatment was associated with poor kidney prognosis.
Autor:innen und Institutionen
- Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.
- Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
- Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
- Clinic of Nephrology and Renal Transplantation, Laiko General Hospital, Athens, Greece.
- Complex Glomerular Disease Unit (CSUR), Nephrology and Renal Transplant Department Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
- Nephrology Department, Fundación Puigvert, Autónoma de Barcelona University, Barcelona, Spain.
ORCID-Profile: Philipp Gauckler, Anna Matyjek, Seleni Kapsia, Luis F Quintana, Montserrat M Diaz, Catherine King, Siân Griffin, Raja Ramachandran, Kathrin Eller, Ayşe Serra Artan, Safak Mirioglu, Martin Busch, Kultigin Turkmen, Chee Kay Cheung, Gema Fernandez Juarez, Julio Pascual, Pilar Auñón, Antolina Rodriguez, Federico Alberici, Leonella Luzardo, Ulf Schönermarck, Jai Radhakrishnan, Karina Guaman, Yonatan Peleg, Léa Hoisnard, Vincent Audard, Vladimir Tesar, Annette Bruchfeld, Maria Stangou, Georgios Lioulios, Stanislas Faguer, Sofiane Salhi, Martin Windpessl, Nikola Zagorec, Andreas Kronbichler
Zitieren
APA
Gauckler, P., Matyjek, A., Kapsia, S., Marinaki, S., Quintana, L. F., Diaz, M. M., King, C., Griffin, S., Ramachandran, R., Odler, B., Eller, K., Artan, A. S., Mirioglu, S., Busch, M., Schaepe, M., Turkmen, K., Cheung, C. K., Pepper, R. J., Juarez, G. F., …, & RITERM Study Team (2025). Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies. Journal of the American Society of Nephrology, 36(4), 668-678. https://doi.org/10.1681/asn.0000000520
Vancouver
Gauckler P, Matyjek A, Kapsia S, Marinaki S, Quintana LF, Diaz MM, et al. Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies. Journal of the American Society of Nephrology. 2025;36(4):668-678. doi:10.1681/asn.0000000520
BibTeX
@article{Gauckler2025,
author = {Gauckler, Philipp and Matyjek, Anna and Kapsia, Seleni and Marinaki, Smaragdi and Quintana, Luis F and Diaz, Montserrat M and King, Catherine and Griffin, Siân and Ramachandran, Raja and Odler, Balazs and Eller, Kathrin and Artan, Ayşe Serra and Mirioglu, Safak and Busch, Martin and Schaepe, Maxi and Turkmen, Kultigin and Cheung, Chee Kay and Pepper, Ruth J and Juarez, Gema Fernandez and Pascual, Julio and Auñón, Pilar and García-Carro, Clara and Rodriguez, Antolina and Alberici, Federico and Luzardo, Leonella and Chebotareva, Natalia and Schönermarck, Ulf and Fernández, Loreto and Radhakrishnan, Jai and Guaman, Karina and Peleg, Yonatan and Hoisnard, Léa and Audard, Vincent and Papasotiriou, Marios and Krnanska, Nina and Tesar, Vladimir and Hruskova, Zdenka and Bruchfeld, Annette and Stangou, Maria and Lioulios, Georgios and Faguer, Stanislas and Ribes, David and Salhi, Sofiane and Windpessl, Martin and Galešić, Krešimir and Crnogorac, Matija and Zagorec, Nikola and Mayer, Gert and Kronbichler, Andreas and RITERM Study Team, RITERM Study Team},
title = {Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies},
journal = {Journal of the American Society of Nephrology},
year = {2025},
volume = {36},
number = {4},
pages = {668--678},
doi = {10.1681/asn.0000000520}
}
EUVIMED